Episode Description:In this week’s Markintel Pulse briefing (Week of Jan 30, 2026), we break down the shift from "AI Pilots" to "Critical Infrastructure."

Key Signals Covered:

• The "Outcomes" Breakthrough: The MASAI trial reports a ~12% reduction in interval cancer rates with AI-supported mammography. We discuss why this "outcome-grade" evidence is the new bar for tenders.
• Reimbursement Wins: CPT 75577 (Category I) is effective for Coronary Plaque AI. We analyze why billing pathways are driving adoption faster than clinical utility alone.
• The Rise of "Quant": New clearances from Spectrum Dynamics (SPECT/CT noise reduction) and MIM Software (Tumor Burden) signal that quantification is winning over simple detection.
• Marketstrat Analysis: Why "Capital Discipline" (InMode, Resonetics) is driving consolidation in the background.

Strategic Takeaway:Outcomes evidence is now a contracting weapon. Vendors without hard data on interval cancers or throughput speed (scan time reduction) will be priced as commodities.

Read the full analysis:https://marketstrat.com/articles-news/markintel-pulse-insights-imaging-ai-becomes-infrastructure-jan-30-2026/

In this week’s Markintel Pulse briefing (Week of Jan 23, 2026), we analyze the structural shift in Radiology AI from single-point "apps" to enterprise-grade platforms.

Key Signals Covered:

• The Platform Win: Aidoc secures FDA clearance for its "Comprehensive Abdomen CT Triage," bundling 14 clinical findings into a single workflow. We discuss why "Integration Fatigue" is driving the market toward bundles.

• Pharma Enters the Chat: Bristol Myers Squibb and Microsoft launch the "Precision Imaging Network" for lung cancer. This signals that imaging data is evolving into a pharma-grade biomarker asset.

• The Hidden ROI: Post-Cures Act data shows patient outreach to radiologists has spiked 39%. We explain why the "Explainability Layer" (GenAI for patient communication) is the next immediate capacity lever for health systems.

Strategic Takeaway:Budget owners are no longer buying algorithms; they are buying operating leverage. The winners in 2026 will be those who can package triage, orchestration, and reporting into a single contract.

Read the full visual analysis:https://marketstrat.com/articles-news/markintel-pulse-insights-radiology-ai-shifts-from-apps-to-platforms-jan-23-2026/

This Week on the Pulse:

• MRI Automation: Why Vista AI's $29.5M raise signals a shift from "detection" to "capacity."

• Strategic M&A: Inside Boston Scientific’s $14.5B acquisition of Penumbra.

• Tech Layer: Google releases MedGemma 1.5—what open models mean for your competitive moat.

About This Episode:This briefing is based on the "Markintel Pulse Insights" published on January 16, 2026.

Read the full data set: https://marketstrat.com/articles-news/markintel-pulse-insights-mri-automation-becomes-the-capacity-lever-jan-16-2026/#

Disclaimer: This podcast is produced by Marketstrat Inc. The voice narration is AI-generated ("Marcus" / "Zara") to deliver our latest research to you faster.